anses
AGENCE NATIONALE DU
MEDICAMENT VETERINAIRE

FRENCH AGENCY FOR FOOD, ENVIRONNEMENTAL AND OCCUPATIONAL HEALTH SAFETY

FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS

14 RUE CLAUDE BOURGELAT – PARC D'ACTIVITES DE LA GRANDE MARCHE JAVENE – CS 70611 – 35306 FOUGERES

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

MACROFENCE 1.25 G + 0.56 G MEDICATED COLLAR FOR CATS
MACROFENCE 1.25 G + 0.56 G MEDICATED COLLAR FOR DOGS UP TO 8 KG
MACROFENCE 4.50 G + 2.03 G MEDICATED COLLAR FOR DOGS OVER 8 KG

27 June 2025

PRODUCT SUMMARY

EU procedure number	FR/V/0508/001-003/DC
Name, strength and pharmaceutical form	Macrofence 1.25 g + 0.56 g, medicated collar for cats Macrofence 1.25 g + 0.56 g, medicated collar for dogs up to 8kg Macrofence 4.50 g + 2.03 g, medicated collar for dogs over 8 kg
Applicant	ALFAMED 13 EME RUE LID 06517 CARROS CEDEX, FRANCE
Active substance(s)	imidacloprid /flumethrin
ATC vetcode	QP53AC55
Target species	Cats, dogs
Indication for use	**For cats** with or at risk from mixed infestation by fleas and ticks targeted by each of the combined active substances. The veterinary medicinal product is only indicated when used against the target pathogens at the same time. Treatment of flea infestation and prevention of flea re-infestation (*Ctenocephalides felis*) due to insecticidal activity for 7 to 8 months. Protects the animal's immediate surroundings against flea larvae development for 10 weeks. The veterinary medicinal product can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD) where this has been previously diagnosed by a veterinarian. Prevention of re-infestation with ticks (*Ixodes ricinus*) through acaricidal (killing) effect and through repellent (anti-feeding) effect from 2 days to 8 months. Prevention of re-infestation with ticks (*Rhipicephalus turanicus*) through acaricidal (killing) effect from 2 days to 8 months. It is effective against larvae, nymphs and adult ticks. **For dogs** with or at risk from mixed infestation by fleas, ticks, lice and sandflies targeted by each of the combined active substances. The veterinary medicinal product is only indicated when used against the target pathogens at the same time. Treatment of flea infestation and prevention of flea re-infestation (*Ctenocephalides canis*, *Ctenocephalides felis*) due to insecticidal activity for 7 to 8 months Protects the animal's immediate surroundings against flea larvae development for 8 months. The veterinary medicinal product can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD) where it has been previously diagnosed by a veterinarian. Prevention of re-infestation with ticks (*Ixodes ricinus*, *Rhipicephalus sanguineus*) through acaricidal (killing) effect and through repellent (anti-feeding) effect from 2 days to 8 months.

	Prevention of re-infestation with ticks (*Dermacentor reticulatus*) through acaricidal (killing) effect from 2 days to 8 months. It is effective against larvae, nymphs and adult ticks. Reduction of the risk of transmission of the pathogens *Babesia canis vogeli* and *Ehrlichia canis* thereby reducing the risk of canine babesiosis and canine ehrlichiosis for 7 months through acaricidal and repellent effects on the tick vector *Rhipicephalus sanguineus* .The effect is indirect due to the product's activity against the vector. Reduction of the risk of transmission of the pathogen *Leishmania infantum for up to 8 months thereby reducing the risk of canine leishmaniosis, by repellent activity on sand-flies.* The effect is indirect due to the product's activity against the vectors. Treatment of infestation by biting lice (*Trichodectes canis*).

MACROFENCE MEDICATED COLLARS	FR/V/0508/001-003/DC
ALFAMED	DCP
Publicly available assessment report	

PRODUCT INFORMATION

The Summary of Product Characteristics (SPC), the labelling and package leaflet for this veterinary medicinal product (VMP) is available in the Union Product Database (UPD).

SUMMARY OF ASSESSMENT

Legal basis of original application*	Hybrid application in accordance with Article 19 of Regulation (EC) 2019/6 as amended.
Reference product (RP)	Seresto 1.25 g + 0.56 g collar for cats, Seresto 1.25 g + 0.56 g collar for dogs ≤ 8 kg, Seresto 4.50 g + 2.03 g for dogs > 8 kg
Marketing authorisation holder	ELANCO GmbH
MS where the RP is or has been authorised	AT, BE, BG, CY, CZ, DE, DK, EE, EL, ES, FI, FR, HU, IE, IS, IT, LT, LU, LV, NL, NO, PL, PT, RO, SE, SI, SK, UK(NI)
Marketing authorisation number EU procedure number	DE/V/0143/001/DC, DE/V/0143/002/DC, DE/V/0143/004/DC
Date of authorisation	27 July 2011
Date of completion of the original decentralised procedure	04 June 2025
Concerned Member States for original procedure	ES, FR, IT, PT, NL
Concerned Member States for subsequent recognition procedure	Not applicable.

*Please be aware that certain parts of the dossier may be varied and consequently be subject to protection of technical documentation – for these and other changes of referenceability to parts of the dossier, please see chapter POST-AUTHORISATION PROCEDURES

1. SCIENTIFIC OVERVIEW

The veterinary medicinal product (VMP) is produced and controlled using validated methods and tests, which ensure the consistency of the VMP released on the market.

It has been shown that the VMP can be safely used in the target species; the reactions observed are indicated in the SPC.

The VMP is safe for the user, and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.

The efficacy of the VMP was demonstrated according to the claims made in the SPC.

The overall risk/benefit analysis is in favour of granting a marketing authorisation.

2. QUALITY DOCUMENTATION (physicochemical, biological or microbiological information)

A. Product description

The veterinary medicinal products are medicated collars containing imidacloprid and flumethrin as active substances. The medicated collars for cats or dogs up to 8 kg contain 1.25 g imidacloprid and 0.56 g flumethrin and the excipients di-n-butyl adipate, propylene glycol dicaprylocaprate, epoxidized soybean oil, stearic acid, titanium dioxide, iron oxide black, iron oxide brown, iron oxide yellow and polyvinyl chloride. The medicated collars for dogs above 8 kg contain 4.5 g imidacloprid and 2.025 g flumethrin and the excipients di-n-butyl adipate, propylene glycol dicaprylocaprate, epoxidized soybean oil, stearic acid, titanium dioxide, iron oxide black, iron oxide brown, iron oxide yellow and polyvinyl chloride.

The collars are individually packed in a sealed aluminium plastic sachet placed in an outer carton box.

The choice of the formulation is justified.

The VMP is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

B. Description of the manufacturing method

The VMP is manufactured fully in accordance with the principles of good manufacturing practice at a licensed manufacturing site.

Process validation data on the VMP have been presented in accordance with the relevant European guidelines.

C. Production and control of starting materials

The active substances are imidacloprid and flumethrin, two established active substances. Imidacloprid is an established substance described in the European Pharmacopeia. Both active substances are manufactured in accordance with the principles of good manufacturing practice.

The active substances specifications are considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with these specifications have been provided.

Scientific data and certificates of suitability issued by the EDQM have been provided.

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this VMP.

D. Control tests carried out on isolated intermediates during the manufacturing process

Not Applicable.

E. Control tests on the finished product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification and their limits have been justified and are considered appropriate to adequately control the quality of the VMP.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

F. Stability tests

Stability data on the active substances have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substances when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the VMP throughout its shelf life when stored under the approved conditions.

G. Other information

Not Applicable.

3. SAFETY DOCUMENTATION (safety and residues tests)

As this is a hybrid application according to Article 19 of Regulation (EC) 2019/6 and equivalence with a reference VMP has been demonstrated, results of toxicological tests are not required.

The toxicological aspects of this VMP are identical to the reference VMP.

Warnings and precautions as listed on the product literature are adequate to ensure safety of the product to users / the environment.

A. Safety tests

Pharmacological studies

See Part 4.A.

User safety

The applicant has provided a user risk assessment (URA) in compliance with the relevant guidelines.
Toxicity of part of the VMP components has been documented with literature data to support the URA. For the exposure part, the different exposure scenarios were identified and presented.

For the post-application phase, in order to characterise the exposure during animal's petting, a GLP wipe test has been conducted with the final formulation of the proposed VMP.

Special precautions as listed on the product literature are adequate to ensure safety to users of the VMP.

Environmental Risk Assessment

A Phase I environmental risk assessment (ERA) was provided according to the CVMP/VICH guidelines.

Phase I:

The environmental risk assessment can stop in Phase I and no Phase II assessment is required because the VMP will only be used in non-food animals.

B. Residues documentation

Not applicable, as the product is intended for non-food producing species.

4. EFFICACY DOCUMENTATION (preclinical studies and clinical trials)

As this is a hybrid application according to Article 19 of Regulation (EC) 2019/6 and equivalence with the reference VMP has been demonstrated, efficacy studies are not required.

A. Pre-Clinical Studies

Pharmacology

No bioequivalence study was provided as not relevant according to the non-systemic action of the two active substances.

A comparative release study was performed with the candidate product and the reference product, SERESTO according to the Guideline *The quality of modified release dosage forms for veterinary use* (EMA/CVMP/680/02).

An equivalence between the products has been concluded according to the section 7 of the Guideline for testing and evaluation of the efficacy of antiparasitic substances for the treatment and prevention of tick and flea infestation in dogs and cats (EMEA/CVMP/EWP/005/2000).

Development of resistance and related risk in animals

The bibliographic search on possible resistance of claimed target parasites to imidacloprid or/and flumethrin conducted by the applicant did not permit to identify specific emergence of resistance. Adequate warnings as recommended in the Guideline on the summary of product characteristics for antiparasitic veterinary medicinal products (EMA/CVMP/EWP/170208/2005) appear on the product literature.

Tolerance in the target species of animals

The tolerance profile of this VMP is identical to the reference VMP. The product literature accurately reflects the type and incidence of adverse effects, which might be expected.

B. Clinical trials

No clinical trials were performed.

As this is a hybrid application according to Article 19 of Regulation (EC) 2019/6 and equivalence with the reference VMP has been demonstrated, clinical trials are not required.

The efficacy claims for this VMP are equivalent to those of the reference VMP.

5. OVERALL CONCLUSION AND BENEFIT-RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the VMP is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the VMP for humans and the environment is acceptable.